Literature DB >> 12762887

Mitogenic signaling cascades in glial tumors.

Gurpreet S Kapoor1, Donald M O'Rourke.   

Abstract

Gliomas are primary central nervous system tumors that arise from astrocytes, oligodendrocytes, or their precursors. Gliomas can be classified into several groups according to histological features. A number of genetic alterations have been identified in human gliomas; these generally affect either signal transduction pathways activated by receptor tyrosine kinases or cell cycle growth arrest pathways. These observed genetic alterations are now being used to complement histopathological diagnosis. The aim of the present review is to give a broad overview of the receptor tyrosine kinase signaling machinery involved in gliomagenesis, with an emphasis on the cooperative interaction between receptor tyrosine kinase signaling and the cell cycle-regulatory machinery. Understanding molecular features of primary glial tumors will eventually allow for target-selective intervention in distinct glioma subsets and a more rational approach to adjuvant therapies for these refractory diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12762887     DOI: 10.1227/01.neu.0000065135.28143.39

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  18 in total

Review 1.  Malignant glioma: neuropathology and neurobiology.

Authors:  Matthias Preusser; Christine Haberler; Johannes A Hainfellner
Journal:  Wien Med Wochenschr       Date:  2006-06

2.  Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells.

Authors:  Gui Su; Kristy Meyer; Chilkunda D Nandini; Dianhua Qiao; Shahriar Salamat; Andreas Friedl
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

Authors:  Yi Zhan; George J Counelis; Donald M O'Rourke
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

4.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

5.  EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion.

Authors:  Mitsutoshi Nakada; Jared A Niska; Nhan L Tran; Wendy S McDonough; Michael E Berens
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 6.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

7.  IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Authors:  Oren J Becher; Katia M Peterson; Soumen Khatua; Maria R Santi; Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 8.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

9.  Correlation analysis between the expression of P21WAF1/CIP1, P16 proteins and human glioma.

Authors:  Tao Song; Jun Wu; Fang Fang; Fanghua Chen; Lei Huo; Mingyu Zhang; Lei Wu; Zhiyong Zhai; Liang Yang; Jiesheng Fang
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

10.  The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors.

Authors:  Caroline Piette; Manuel Deprez; Thierry Roger; Agnès Noël; Jean-Michel Foidart; Carine Munaut
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.